Competitive Grants Program
Pfizer supports the global healthcare community’s independent initiatives (e.g., research, quality improvement or education) to improve patient outcomes in areas of unmet medical need that are aligned with Pfizer’s medical and/or scientific strategies.
Pfizer’s competitive grant program involves a publicly posted Request for Proposal (RFP) that provides detail regarding a specific area of interest and sets timelines for review and approval. Organizations are invited to submit an application addressing the specific gaps in research, practice or care as outlined in the specific RFP. The grant requester (and ultimately the grantee) is responsible for the design, implementation, sponsorship, and conduct of the independent initiative supported by the grant, including compliance with any regulatory requirements.
Sign up to receive all grant announcements, including Request for Proposal (RFP) postings.
Sign Up for Alerts DetailsTitle Grant Type Focus Area Country Application Due Date Optimizing Antimicrobial Stewardship (AMS) Interventions and Outcomes in Clinical Outcomes, Optimal Use and Resource UtilizatioRelease Date:Research Inflammation & Immunology China Optimizing Disease Management to Improve Alopecia Areata Quality of CareRelease Date:Quality Improvement Inflammation & Immunology China Research on Exploring Disease Assessment and Prioritizing Systematic Treatment for VitiligoRelease Date:Research Inflammation & Immunology China Quality Improvement in Molecular Testing Pathways for Metastatic Colorectal Cancer (mCRC)Release Date:Partner: American Society for Clinical Pathology (ASCP)Quality Improvement Oncology USA Personalized monitoring&treatment for HR+, HER2- mBC patients treated w CDK4/6i: incorporating Patient complexity risk factorsRelease Date:Quality Improvement, Research Oncology Italy Providing Appropriate Medical Care for IBD PatientsRelease Date:Partner: Japanese Society for Inflammatory Bowel Disease (JSIBD)Quality Improvement Inflammation & Immunology Japan Administration of brentuximab vedotin alone or in combination with other approved agents in pre and/or peri CAR-TRelease Date:Research Oncology USA Fostering Educational Initiatives for ALK+ Metastatic Non-Small Cell Lung Cancer(mNSCLC) Tyrosine Kinase Inhibitors(TKI) TherapyRelease Date:Education Oncology Canada 2026 Inflammatory Bowel Disease (IBD) Fellowship- United StatesRelease Date:Fellowship Inflammation & Immunology USA Title Grant Type Focus Area Country Application Due Date Accelerating biomarker testing for optimized metastatic colorectal cancer treatment planning across CanadaRelease Date:Partner: Colorectal Cancer Canada (CCC)Quality Improvement, Research Oncology Canada Integrin beta-6 (IB6) Sigvotatug Vedotin (SV) Translational and Pre-Clinical ResearchRelease Date:Research Oncology All 2025 Inflammatory Bowel Disease (IBD) Fellowship – United StatesRelease Date:Fellowship Inflammation & Immunology USA PARP-inhibitor Combination Treatments: Efficacy and Safety in a New Era of metastatic Castration Resistant Prostate CancerRelease Date:Education Oncology China Transthyretin Cardiac Amyloidosis Fellowship - United StatesRelease Date:Fellowship Rare Disease USA Advances in Migraine ManagementRelease Date:Education Internal Medicine USA Exploring the Use of Artificial Intelligence (AI) Applications in ALK+ NSCLCRelease Date:Quality Improvement, Research Oncology Italy Sickle Cell Disease (SCD) FellowshipRelease Date:Fellowship Rare Disease USA Global Call for Collaborators – Pfizer RSV OA ResearchRelease Date:Research Vaccines All 2025 Headache Medicine Fellowship - USRelease Date:Fellowship Internal Medicine USA Sickle Cell Disease Visiting Professorship ProgramRelease Date:Education Rare Disease USA Addressing Barriers to Cancer Care for AIAN and NHPI IndividualsQuality Improvement Oncology USA